This study is for men with intermediate- or high-risk prostate cancer who are receiving hormone therapy and radiation. It investigates whether a special imaging test, PSMA PET/CT (an imaging test that uses a radioactive tracer to highlight prostate cancer cells), can help doctors more accurately target remaining cancer with Stereotactic Body Radiation Therapy (SBRT), a precise form of radiation. You would receive standard Androgen Deprivation Therapy (ADT) +/- bicalutamide (hormone therapy to lower testosterone) and SBRT, along with three PSMA PET/CT scans over six months. The main goal is to see how well the PSMA PET/CT imaging helps define the cancer for radiation planning. The study aims to enroll 23 participants, but its current status is unclear.

Study design

This is an interventional study with a planned enrollment of 23 men. It is not specified if it is randomized or blinded.

What's involved

You would receive approximately six months of ADT, five sessions of SBRT over two weeks, and three PSMA PET/CT scans over a six-month period.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 8 weeks from the start of hormone therapy, before radiation begins. Imaging will also be performed at 24 weeks (end of treatment).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.